Search Results

The Legacy of Geoffrey H. White, MD, 1951–2012

Limitations of Implantable Pressure Sensors for EVAR

Before this technology can be widely accepted, issues with respect to reimbursement and efficacy must be addressed.

By Geoffrey H. White, MD

Guest Chief Medical Editor's Page

Trends in Embolization

By Jafar Golzarian, MD

Interview With Geoffrey D. Barnes, MD, MSc

The University of Michigan vascular cardiologist discusses PERT research needs, implementation science in practice, anticoagulation stewardship, and collaborative patient care.

Stent Graft Use in a Posttrauma Pseudoaneurysm

Management of an arteriovenous fistula and pseudoaneurysm 14 years after traumatic injury.

By Mojtaba Gashti, DO, and Jeffrey Stephenson, MS

Tissue-Engineered Vascular Grafts for Dialysis Access

Jeffrey H. Lawson, MD, PhD, discusses the present status of this technology and its path from concept to reality.

With Jeffrey H. Lawson, MD, PhD

New Developments in Hemodialysis Grafts

The latest technologies for treating patients with end-stage renal disease.

By Shawn M. Gage, PA-C, and Jeffrey H. Lawson, MD, PHD

Approaches to Treating Challenging Iliofemoral Lesions

Interventionists must be prepared to handle access difficulties and procedural complications.

By Aravinda Nanjundappa, MD, RVT; Steven C. Powell, MD; Michael Stoner, MD; Sangeeta Mandapaka, MD; Jeffrey H. Freihage, MD; and Robert S. Dieter, MD, RVT

Outpatient CLI Revascularization in the United States

The benefit of office interventional suites to the complex and at-risk CLI patient.

By Jeffrey Carr, MD; William H. Julien, MD; Arthur C. Lee, MD; Jeffrey Wang, MD; and Lynne Mercadante, RN

Endovascular Repair of Ruptured Descending Thoracic Aneurysms

Recent literature supports a TEVAR-first approach for this rare, life-threatening condition.

By Jasper W. Van Keulen, MD; Frederik H.W. Jonker, MD; Jeffrey Indes, MD; and Bart E. Muhs, MD, PhD

Embolic Protection Device Technology

An overview of current device designs and the philosophies behind them.

By Jeffrey A. Southard, MD, and Garrett B. Wong, MD

cTACE: The Rebirth of Lipiodol?

Lipiodol-based cTACE remains the most well-studied transarterial therapy for hepatocellular carcinoma.

By Ali Kord Valeshabad, MD, MPH; Jeffrey Kuwahara, MD; and Charles E. Ray Jr, MD, PhD, MS

Venous Disease: The Year in Review

An exploration of significant advances, challenges, and future directions in venous disease management.

By Jacob J. Bundy, MD, MPH; Ravi N. Srinivasa, MD, FSIR; Mark H. Meissner, MD; John M. Moriarty, MD, FSIR; and Jeffrey Forris Beecham Chick, MD, MPH